Raritan, NJ (July 1, 2011) - Janssen Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XARELTO® (rivaroxaban tablets), a novel, once-daily, oral ...

The Food and Drug Administration has given tentative approval to Alembic's rivaroxaban tablets in dosage strengths of 10 mg, 15 mg, and 20 mg. The product is the generic of Janssen’s Xarelto tablets, ...

Lupin is introducing rivaroxaban tablets, 2.5 mg, which is the generic of Janssen’s Xarelto. The medication is used to reduce the risk of major cardiovascular events in patients with coronary artery ...

The approval is only for the 2.5mg tablet. The Food and Drug Administration (FDA) has approved the first generics of Xarelto ® (rivaroxaban) 2.5mg. Xarelto 2.5mg is used, in combination with aspirin, ...

The U.K. has approved an oral suspension version of Bayer’s anticoagulant Xarelto to treat venous thromboembolism (VTE) in children. Bayer developed the formulation to eliminate the need for kids with ...

XARELTO (rivaroxaban) 20mg tablets Janssen Pharmaceuticals announced FDA approval of Xarelto (rivaroxaban) tablets for the prevention of deep vein thrombosis (DVT) that may lead to a pulmonary ...

Mumbai, Aug. 13 -- The approval covers strengths of 2.5 mg, 10 mg, 15 mg, and 20 mg. The approved tablets are bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Xarelto ...

XARELTO® is the only new oral anticoagulant with FDA approval in this indication Raritan, NJ (July 1, 2011) /PRNewswire/ - Janssen Pharmaceuticals, Inc. announced today that the U.S. Food and Drug ...